Polyrizon shares are trading higher after the company reported preclinical results showing its Trap & Target formulation achieved targeted deposition in the upper nasal cavity.
Polyrizon shares are trading higher after the company reported preclinical results showing its Trap & Target formulation achieved targeted deposition in the upper nasal cavity.